These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 27125358)

  • 1. Comparison of metastatic neuroendocrine neoplasms to the breast and primary invasive mammary carcinomas with neuroendocrine differentiation.
    Mohanty SK; Kim SA; DeLair DF; Bose S; Laury AR; Chopra S; Mertens RB; Dhall D
    Mod Pathol; 2016 Aug; 29(8):788-98. PubMed ID: 27125358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metastatic breast cancer simulating well-differentiated neuroendocrine neoplasms of visceral organs.
    Cloutier J; Thompson ED; Cimino-Mathews A; Rooper LM; Matoso A; Argani P
    Hum Pathol; 2018 Dec; 82():76-86. PubMed ID: 30031098
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunohistochemical expression of estrogen and progesterone receptors in primary pulmonary neuroendocrine tumors.
    Sica G; Wagner PL; Altorki N; Port J; Lee PC; Vazquez MF; Saqi A
    Arch Pathol Lab Med; 2008 Dec; 132(12):1889-95. PubMed ID: 19061285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterisation of GATA3 expression in invasive breast cancer: differences in histological subtypes and immunohistochemically defined molecular subtypes.
    Shaoxian T; Baohua Y; Xiaoli X; Yufan C; Xiaoyu T; Hongfen L; Rui B; Xiangjie S; Ruohong S; Wentao Y
    J Clin Pathol; 2017 Nov; 70(11):926-934. PubMed ID: 28428285
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metastatic neuroendocrine tumour in the breast: a potential mimic of in-situ and invasive mammary carcinoma.
    Perry KD; Reynolds C; Rosen DG; Edgerton ME; T Albarracin C; Gilcrease MZ; Sahin AA; Abraham SC; Wu Y
    Histopathology; 2011 Oct; 59(4):619-30. PubMed ID: 22014043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unusual apocrine carcinoma with neuroendocrine differentiation: a cutaneous neoplasm may be analogous to neuroendocrine carcinoma with apocrine differentiation of breast.
    Li Y; Chen LL; Li B; Tian XY; Li Z
    Diagn Pathol; 2015 Jun; 10():64. PubMed ID: 26055980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic utility and sensitivities of matrix Gla protein (MGP), TRPS1 and GATA3 in breast cancer: focusing on metastatic breast cancer, invasive breast carcinoma with special features, and salivary gland-type tumours.
    Wu Y; Chen F; Pan L; Chao X; Li M; Luo R; Chen K; Zheng C; Du T; He J; Sun P
    Pathology; 2024 Jun; 56(4):516-527. PubMed ID: 38570266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simultaneous carcinomas of the breast and ovary: utility of Pax-8, WT-1, and GATA3 for distinguishing independent primary tumors from metastases.
    Espinosa I; Gallardo A; D'Angelo E; Mozos A; Lerma E; Prat J
    Int J Gynecol Pathol; 2015 May; 34(3):257-65. PubMed ID: 25844549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utility of uroplakin II expression as a marker of urothelial carcinoma.
    Tian W; Guner G; Miyamoto H; Cimino-Mathews A; Gonzalez-Roibon N; Argani P; Li X; Sharma R; Subhawong AP; Rezaei K; Bivalacqua TJ; Epstein JI; Bishop JA; Netto GJ
    Hum Pathol; 2015 Jan; 46(1):58-64. PubMed ID: 25449628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GATA3: a multispecific but potentially useful marker in surgical pathology: a systematic analysis of 2500 epithelial and nonepithelial tumors.
    Miettinen M; McCue PA; Sarlomo-Rikala M; Rys J; Czapiewski P; Wazny K; Langfort R; Waloszczyk P; Biernat W; Lasota J; Wang Z
    Am J Surg Pathol; 2014 Jan; 38(1):13-22. PubMed ID: 24145643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GATA3 immunohistochemistry expression in histologic subtypes of primary breast carcinoma and metastatic breast carcinoma cytology.
    Deftereos G; Sanguino Ramirez AM; Silverman JF; Krishnamurti U
    Am J Surg Pathol; 2015 Sep; 39(9):1282-9. PubMed ID: 26274030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Spindle cell carcinoma of breast with neuroendocrine differentiation].
    Ding HY; Gao LX
    Zhonghua Bing Li Xue Za Zhi; 2006 Jan; 35(1):13-7. PubMed ID: 16608642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical, histopathologic, and immunohistochemical features of microglandular adenosis and transition into in situ and invasive carcinoma.
    Khalifeh IM; Albarracin C; Diaz LK; Symmans FW; Edgerton ME; Hwang RF; Sneige N
    Am J Surg Pathol; 2008 Apr; 32(4):544-52. PubMed ID: 18300793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GATA3 expression in breast carcinoma: utility in triple-negative, sarcomatoid, and metastatic carcinomas.
    Cimino-Mathews A; Subhawong AP; Illei PB; Sharma R; Halushka MK; Vang R; Fetting JH; Park BH; Argani P
    Hum Pathol; 2013 Jul; 44(7):1341-9. PubMed ID: 23375642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Solid neuroendocrine carcinomas of the breast: metastases or primary tumors?
    Richter-Ehrenstein C; Arndt J; Buckendahl AC; Eucker J; Weichert W; Kasajima A; Schneider A; Noske A
    Breast Cancer Res Treat; 2010 Nov; 124(2):413-7. PubMed ID: 20872069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GATA-3 and FOXA1 expression is useful to differentiate breast carcinoma from other carcinomas.
    Davis DG; Siddiqui MT; Oprea-Ilies G; Stevens K; Osunkoya AO; Cohen C; Li XB
    Hum Pathol; 2016 Jan; 47(1):26-31. PubMed ID: 26527523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuroendocrine Tumors of the Breast.
    Rosen LE; Gattuso P
    Arch Pathol Lab Med; 2017 Nov; 141(11):1577-1581. PubMed ID: 29072945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuroendocrine differentiation in pure type mammary mucinous carcinoma is associated with favorable histologic and immunohistochemical parameters.
    Tse GM; Ma TK; Chu WC; Lam WW; Poon CS; Chan WC
    Mod Pathol; 2004 May; 17(5):568-72. PubMed ID: 15001999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of Oncotype DX and Mammostrat risk estimations and correlations with histologic tumor features in low-grade, estrogen receptor-positive invasive breast carcinomas.
    Acs G; Kiluk J; Loftus L; Laronga C
    Mod Pathol; 2013 Nov; 26(11):1451-60. PubMed ID: 23743933
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of estrogen receptor, progesterone receptor and HER2 results in concurrent ipsilateral samples with invasive breast carcinoma: a retrospective study of 246 biopsies from 119 patients.
    Singh K; Wang Y; Marketkar S; Kalife ET; Steinhoff MM
    Hum Pathol; 2017 Jul; 65():123-132. PubMed ID: 28457730
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.